Details and Advantages
Applications:
ELISA,Flow Cyt
Reactivity:
Human/Cynomolgus
Conjugate:
Unconjugated
Advantages:
High lot-to-lot consistency
Increased sensitivity and higher affinity
Animal-free production
Summary
>
Description:
Anti-Claudin-18.2, AlpHcAbs® Human antibody is designed for detecting human Claudin-18.2 specifically. Anti-Claudin-18.2, AlpHcAbs® Human antibody is recombinant VHH domain of alpaca IgG2b/2c fused to Human IgG1 Fc. Based on ELISA, Anti-Claudin-18.2, AlpHcAbs® Human antibody reacts with human Claudin-18.2, and has reactivity with cynomolgus Claudin-18.2.
Immunogen: Recombinant human Claudin-18.2
Host: Alpaca pacous
Isotype: VHH domain of alpaca IgG2b/2c fused to Human IgG1 Fc(mutation)
Conjugate: Unconjugated
Specificity: Human Claudin-18.2
Cross-Reactivity: Cross-reactivity with cynomolgus 18.2
Purity: Recombinant Expression and Affinity purified
Concentration: 1mg/ml
Formation: Liquid, 10mM PBS (pH 7.5), 0.05% sucrose, 0.1% trehalose, 0.01% proclin300, 50% Glycerol
Storage: Store at –20 °C, (Avoid freeze / thaw cycles), Stable for 12 months at -20°C
Background:
The Claudin-18.2 (CLDN 18.2) is an isoform of Claudin 18, and belongs to the tight junction protein family. The Claudin-18.2 is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, such as gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer and non-small-cell lung cancer. Claudin-18.2 participates in the proliferation, differentiation and migration of tumor cells. Recent studies have identified Claudin-18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors.
Using antibody with Fc(mutation), the background from Fc receptors will be eliminated.
Anti-Claudin-18.2, AlpHcAbs® Human antibody is designed for detecting human Claudin-18.2 specifically. Anti-Claudin-18.2, AlpHcAbs® Human antibody is recombinant VHH domain of alpaca IgG2b/2c fused to Human IgG1 Fc. Based on ELISA, Anti-Claudin-18.2, AlpHcAbs® Human antibody reacts with human Claudin-18.2, and has reactivity with cynomolgus Claudin-18.2.
Immunogen: Recombinant human Claudin-18.2
Host: Alpaca pacous
Isotype: VHH domain of alpaca IgG2b/2c fused to Human IgG1 Fc(mutation)
Conjugate: Unconjugated
Specificity: Human Claudin-18.2
Cross-Reactivity: Cross-reactivity with cynomolgus 18.2
Purity: Recombinant Expression and Affinity purified
Concentration: 1mg/ml
Formation: Liquid, 10mM PBS (pH 7.5), 0.05% sucrose, 0.1% trehalose, 0.01% proclin300, 50% Glycerol
Storage: Store at –20 °C, (Avoid freeze / thaw cycles), Stable for 12 months at -20°C
Background:
The Claudin-18.2 (CLDN 18.2) is an isoform of Claudin 18, and belongs to the tight junction protein family. The Claudin-18.2 is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, such as gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer and non-small-cell lung cancer. Claudin-18.2 participates in the proliferation, differentiation and migration of tumor cells. Recent studies have identified Claudin-18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors.
Using antibody with Fc(mutation), the background from Fc receptors will be eliminated.
Performance
>
ELISA: 1:4,000-1:10000
Flow Cytometry：1:200-1:1000
Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.
Flow Cytometry：1:200-1:1000
Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.
